Filter by

Type of content

Include documents

Categories
Document type
Topics
Responsible body
Last updated
First published

Search results (28117)

EMEA-001811-PIP03-20 - paediatric investigation plan
Active substance: ligelizumab
Therapeutic area: Pneumology-allergology
Pharmaceutical form(s): Solution for injection, Age appropriate dosage form for parenteral use
Route(s) of administration: Subcutaneous use
Decision number: P/0372/2021
Decision date: 8 September 2021
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance check done: No
Last updated: 10 April 2026
PIPHuman
Mysimba
INN or common name: naltrexone; bupropion
Therapeutic area (MeSH): Obesity; Overweight
Marketing authorisation issued:
Last updated: 10 April 2026
Revision: 32
Additional monitoring
MedicineHumanAuthorised